Women with suspected coronary artery disease (CAD) who report taking antidepressant and anti-anxiety medications have an increased risk of cardiovascular events, including heart attacks and strokes, and death compared to women not taking these medications, according to researchers at the Uniformed Services University of the Health Sciences (USU).

Their paper, “Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease,” reports recent findings from the Women’s Ischemia Syndrome Evaluation (WISE) study. The WISE study, sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, involves investigators at multiple study sites around the U.S., and was designed to develop methods for improved assessment and understanding of coronary artery disease in women.

According to the paper’s first author David S. Krantz, Ph.D., Professor and Chairman, Department of Medical and Clinical Psychology at USU, there are several important implications of this research for women with suspected CAD. However, he also emphasized this was a correlational study and not a clinical trial, so this study’s results are not definitive.

“Since depression is an important risk factor for CAD morbidity and mortality, women with suspected CAD may be inadequately treated for depression,” said Dr. Krantz. “Taking these medications may be a marker of residual depression and residual depression in these women may account for increased CAD events. However, it needs to be considered that taking antidepressant and anti-anxiety medications may not be beneficial, and may in fact be harmful for some women.”

Dr. Krantz also said women with suspected CAD often have unexplained chest pain, since traditional diagnostic methods for CAD — for example, coronary angiography — may not reveal the presence of disease. More…